Characterization of estrogen receptor-low-positive breast cancer

[1] Bartlett JM(2011)Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial J Clin Oncol 29 1531-1538

[2] Brookes CL(2004)Prognostic and predictive factors in early-stage breast cancer Oncologist 9 606-616

[3] Robson T(1999)Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474-1481

[4] van de Velde CJ(2000)Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 966-978

[5] Billingham LJ(2011)Incidence of breast cancer in the United States: current and future trends J Natl Cancer Inst 103 1397-1402

[6] Campbell FM(2014)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update J Clin Oncol 32 2255-2269

[7] Grant M(2017)Prognostic and predictive value of low estrogen receptor expression in breast cancer Curr Oncol 24 e106-e114

[8] Hasenburg A(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[9] Hille ET(2020)Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution Mod Pathol 34 291-299

[10] Kay C(2010)American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-2795

[1] Bartlett JM(2011)Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial J Clin Oncol 29 1531-1538

[2] Brookes CL(2004)Prognostic and predictive factors in early-stage breast cancer Oncologist 9 606-616

[3] Robson T(1999)Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474-1481

[4] van de Velde CJ(2000)Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 966-978

[5] Billingham LJ(2011)Incidence of breast cancer in the United States: current and future trends J Natl Cancer Inst 103 1397-1402

[6] Campbell FM(2014)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update J Clin Oncol 32 2255-2269

[7] Grant M(2017)Prognostic and predictive value of low estrogen receptor expression in breast cancer Curr Oncol 24 e106-e114

[8] Hasenburg A(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[9] Hille ET(2020)Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution Mod Pathol 34 291-299

[10] Kay C(2010)American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-2795